New antibody drug shows promise against aggressive prostate cancer
This digest was compiled by AI from multiple sources — links to the originals are below.
Researchers at Umeå University have developed a fully human antibody that halted tumor growth and prevented metastasis in preclinical models of aggressive prostate cancer. The drug, described in Signal Transduction and Targeted Therapy, targets a newly identified mechanism that may reduce side effects. Further safety studies and regulatory approvals are needed before human trials can begin.
The Antibody Mechanism
The fully human antibody was developed by a team led by Professor Maréne Landström at Umeå University's Department of Medical Biosciences. In preclinical studies, the drug stopped both tumor growth and metastatic spread in aggressive prostate cancer models. The antibody works through a newly identified mechanism that the researchers believe may carry a lower risk of side effects compared to existing therapies.
Development Pathway
The findings were published July 20 in Signal Transduction and Targeted Therapy. Drug development specialists at the SciLifeLab Drug Discovery and Development Platform contributed to creating the antibody. Landström noted that several important stages remain, including additional safety studies and approval from regulatory authorities in Europe or the United States.
Clinical Context
Prostate cancer is among the most frequently diagnosed cancers in men. While many tumors grow slowly, aggressive forms can spread to lymph nodes and bones. The broader goal of the project is to improve survival and quality of life for patients with advanced prostate cancer, a process that has involved multiple research organizations and funding partners over several years.
What's Next
The research team plans to conduct additional safety studies before seeking regulatory approval for human trials. It remains unclear how long the approval process will take or whether the antibody will prove effective in patients.
1 source
New antibody drug shows promise against aggressive prostate cancer
